News & Updates
Filter by Specialty:
Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma
The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.
Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma
25 Jan 2022
Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
The risk stratification criteria used in the CHAARTED and LATITUDE trials can accurately assess prognosis in patients with castration-resistant prostate cancer (CRPC), but are insufficient to differentiate between the therapeutic outcomes of androgen receptor pathway inhibitors (ARPI) and docetaxel, a new study has found.
Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
24 Jan 2022
PSA mRNA in circulating tumour cells a potential new biomarker for prostate cancer progression
Levels of prostate specific antigen (PSA) mRNA in circulating tumour cells can be used alongside serum PSA protein levels to refine the assessment of disease progression in patient with metastatic castration-resistant prostate cancer (mCRPC), a new study has found.
PSA mRNA in circulating tumour cells a potential new biomarker for prostate cancer progression
23 Jan 2022
Mild autonomous cortisol secretion common in women with benign adrenal tumour
Mild autonomous cortisol secretion (MACS), a cardiometabolic risk condition, mainly affects women with benign adrenal tumour and requires regular assessment for hypertension and type 2 diabetes (T2D), reveals a study.
